

**PROVISIONAL TECHNICAL EVALUATION REPORT FOR T NO 123 (General Medicines)**

S.NO	Firm Name	Item Code	Item Name	Item Remarks	Status
1	BAXALTA BIOSCIENCE INDIA PVT LTD	Firmm Remarks: May be Considered			
		3001	Anti Hemophilic Factor VIII with vWF (Human) 250 IU Vials	May be considered after submission of valid product license for Anti Hemophilic Factor VIII with vWF (Human) 250 IU	May not be considered
2	BRIYOSIS SOFT CAPS PRIVATE LIMITED	Firmm Remarks: The license validity certificate submitted by the applicant mentioning that, the firm has applied for Retention for the period 24/02/21 to 23/02/26 and the license will continue to be inforce until orders are passed on the application. Hence, the firm may be considered only after submisison of Proper Retention/Renewal certificate with valid product license.			
		4046	Vitamin D 60k	May be considered only after submisison of Proper Retention/Renewal certificate with valid product license.	May not be considered
3	Grifols India Healthcare Pvt Ltd	Firm Remarks: May be considered after submission of (1) Valid GMP certificate for the facility M/s Grifols Biologicals LLC,CA,USA (Import lic no: 1L/B10000115-RC/B10-000106) (2) Annexure-IV signed by CA			
		3001	Anti Hemophilic Factor VIII with vWF (Human) 250 IU Vials	May be considered for the product from M/s Grifols Biologicals LLC,CA,USA (Import lic no: 1L/B10000115-RC/B10-000106)	May be considered
4	JOHNSON AND SMITH CO	Firm Remarks: The firm submitted Retention of manufacturing drug license in Form 25 and 28 valid upto 24.07.2023 and 04.03.2025 respectively. However, the product license for item code:736 was issued on 07.05.2014. Hence, may be considered only after submission of valid license for product under item code:736			
		736	Albendazole Tablets 400 mg Chewable	May be considered after submission of valid product license	May not be considered
5	NESTOR PHARMACEUTICALS LIMITED	Firmm Remarks: May be Considered			
		736	Albendazole Tablets 400 mg Chewable	May be considered after submission of valid product approval copy	May not be considered
		1519	Primaquine Tablets IP 7.5 mg	May be considered after submission of valid product approval copy	May not be considered
6	Reliance life sciences pvt ltd	Firm Remarks: The firm submitted product license for Factor VIII fraction IP 250 IU only. Hence, the firm may be considered after submission of valid product license for specification Anti Hemophilic Factor VIII with vWF (Human)			

S.NO	Firm Name	Item Code	Item Name	Item Remarks	Status
		3001	Anti Hemophilic Factor VIII with vWF (Human) 250 IU Vials	May be considered after submission of valid product license for Factor VIII with vWF	May not be considered
7	REVAT LABORATORIES PRIVATE LIMITED	Firmm Remarks: May be Considered			
		736	Albendazole Tablets 400 mg Chewable		May be considered
8	Sandoz Private Limited	Firmm Remarks: The firm has submitted Literature that Crizanlizumab is a P-Selectin inhibitor and used for sickle cell Anemia. Hence the firm may be considered			
		3006	Monoclonal antibody for P Selectin inhibition for sickle cell inj 100mg vial		May be considered
9	SEEKO BIOTICS	Firmm Remarks: May be Considered after submission of Annexure-III & Annexure-V for item code:1519			
		736	Albendazole Tablets 400 mg Chewable		May be considered
		1519	Primaquine Tablets IP 7.5 mg	May be considered after submission of data for the item under Annexure-III and Annexure-V	May not be considered

**Note:** All the bidders are hereby requested to verify the Provisional Technical Evaluation Report and submit their supporting documents on or before 04.00.PM on 17.11.2021 to the email id: tenders.apmsidc@gmail.com with Subject : Reply to T No 123(MED) TEC Report.